Refractory warts: topical or intralesional cidofovir options

Published Date: 02 Mar 2023

New research suggests that cidofovir may be a helpful option for tender joints or joints.

Read Full News

Latest News

Should Biology Replace Organ Labels in Cancer Treatment?

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

PIP Matches PrEP for Low-Risk HIV

The use of medicine at home offers convenience and curbs costs.

Can Physical Activity Improve Skin Cancer Outcomes?

Physical activity is associated with a reduced risk for all-cause mortality and improved survival in patients with skin cancer, a meta-analysis shows.

Healthy Diet May Cut Cancer Survivors’ Premature Aging Risk

A recent study found reduced premature aging among childhood cancer survivors that adhered to established dietary guidelines.

AI Tools Helpful With Prior Auth Letters, Handouts, and More

‘Specify everything you need, do it as if you’re talking to your medical assistant,’ one dermatologist recommends.

Study Identifies Factors Linked to Early Melanoma Recurrence

Several clinicopathologic features beyond tumor thickness and ulceration are associated with recurrence risk in patients with localized stage I-II melanoma.

Todays Updates

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Todays Updates

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Latest News

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

The use of medicine at home offers convenience and curbs costs.

Physical activity is associated with a reduced risk for all-cause mortality and improved survival in patients with skin cancer, a meta-analysis shows.

A recent study found reduced premature aging among childhood cancer survivors that adhered to established dietary guidelines.

‘Specify everything you need, do it as if you’re talking to your medical assistant,’ one dermatologist recommends.

Several clinicopathologic features beyond tumor thickness and ulceration are associated with recurrence risk in patients with localized stage I-II melanoma.

News All Time

NHS to Fund Ruxolitinib for Vitiligo

NICE has recommended topical ruxolitinib for facial non-segmental vitiligo in patients aged 12 or over after a revised cost review.

Lipedema Is Now Recognized as a Chronic Disease

International consensus defines lipedema as a chronic disease; clarifies its biology and diagnosis; and urges standardized care, research, and policy action.

Lilly's Zepbound and Taltz Improve Psoriasis Symptoms, Drive Weight Loss in Study

Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ⁠better results in patients with the skin disease and obesity in a...

Bimekizumab Eases Plaque Psoriasis Symptoms Up to 3 Years

Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with bimekizumab vs secukinumab up to 3 years.

Amivantamab Tied to Diverse Dermatologic Events in NSCLC

Treatment with amivantamab is associated with a broad spectrum of dermatologic adverse events that can be severe in patients with non-small cell lung cancer, a real-world study shows.

Exploring Cutting-Edge Data for New and Emerging Treatments in Chronic Spontaneous Urticaria

Exploring Cutting-Edge Data for New and Emerging Treatments in Chronic Spontaneous Urticaria

Ask the Experts: The Latest Updates in the Pathophysiology and Targeted Treatment of Chronic Spontaneous Urticaria

Ask the Experts: The Latest Updates in the Pathophysiology and Targeted Treatment of Chronic Spontaneous Urticaria

Navigating Chronic Spontaneous Urticaria Diagnosis, Assessment, and Treatment Selection

Navigating Chronic Spontaneous Urticaria Diagnosis, Assessment, and Treatment Selection

Advancing Immune Checkpoint Inhibitor Use in Resectable Melanoma

Advancing Immune Checkpoint Inhibitor Use in Resectable Melanoma

Inside Idiopathic Inflammatory Myopathies (IIMs): From Pathophysiology to Presentation

Inside Idiopathic Inflammatory Myopathies (IIMs): From Pathophysiology to Presentation

From Clinical Suspicion to Classification of Idiopathic Inflammatory Myopathies (IIMs): Biomarkers and Diagnostic Best Practices

From Clinical Suspicion to Classification of Idiopathic Inflammatory Myopathies (IIMs): Biomarkers and Diagnostic Best Practices

From Unmet Needs to Targeted Intervention: Evolving Treatment Strategies in Idiopathic Inflammatory Myopathies (IIMs)

From Unmet Needs to Targeted Intervention: Evolving Treatment Strategies in Idiopathic Inflammatory Myopathies (IIMs)

AAD: American Academy of Dermatology

Collaborative Clinical Conversations: A Virtual Tumor Board Case Challenge on Immunotherapy in Resectable Melanoma

Collaborative Clinical Conversations: A Virtual Tumor Board Case Challenge on Immunotherapy in Resectable Melanoma

EADV: European Academy of Dermatology and Venereology

Dissolving Drug for Hereditary Angioedema Helps Young Kids

Rapid symptom relief and "excellent" safety reported in small phase III trial

Recommended News For You

In early dementia, SSRIs enhance cognition and major depression.

Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer

Immunotherapy in Head and Neck Cancer After Failure of Definitive Therapy.

Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.

Words matter to people living with cancer. Here's how verbal microaggressions affect their mental state

Top FDA Official Exits; SCOTUS Takes Up Obamacare Case; Texas Doc Suspended

'Chemo brain' cognitive issues linked to poor lymphatic-system drainage

Recommended Articles For You

Integrative Cancer Care: Nutrition, Social Work, Care Coordination, and Genetic Counseling 

Unlocking a New Era in Bladder Cancer Treatment: A Review of the TAR-200 Intravesical Drug Delivery System 

AI-Powered Strategies for Precision and Improved Outcomes in Esophageal Cancer, a Global Health Crisis 

A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Testosterone recovery linked to overall survival in high-risk prostate cancer

2.

New research demonstrates a method for screening people at high risk for pancreatic cancer.

3.

Is Laughter Good for Blood Glucose Control?

4.

Future of Lab-Developed Tests Still Taking Shape

5.

a cutting-edge cancer diagnostic tool.

1.

Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern 

2.

Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment

3.

The Benefits and Risks of Thrombolytics: A Comprehensive Guide 

4.

A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology

5.

Harnessing Cuproptosis: A Novel Nanomedicine Strategy for Triple-Negative Breast Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III

2.

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

3.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases

4.

The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot